When using either IRS ≥ 3 or IRS > 0 (the latter representing the overall median IRS value for BP-NEN) as the cut-off for GPER positivity, patients with GPER-positive tumours showed significantly better outcomes than those with GPER-negative tumours (log-rank test: cut-off IRS ≥ 3, p = 0.020; cut-off IRS > 0, p < 0.001). This evidence concerns the gene GPER1 and neoplasm.